NEO-PV 01

Drug Profile

NEO-PV 01

Alternative Names: NEO-PV-01; Neoantigen-based vaccine - Neon Therapeutics; NeoAntigen-peptides; NeoVax; Personalized-neoantigen-cancer-vaccine-Neon-Therapeutics

Latest Information Update: 27 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Broad Institute; Dana-Farber Cancer Institute
  • Developer Bristol-Myers Squibb; Dana-Farber Cancer Institute; Neon Therapeutics
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Bladder cancer; Glioblastoma; Malignant melanoma; Non-small cell lung cancer

Most Recent Events

  • 25 Jul 2017 Apexigen and Neon Therapeutics enter into a clinical trial collaboration for a phase Ib trial in Malignant melanoma
  • 25 Jul 2017 Apexigen and Neon Therapeutics plan a phase Ib trial in Malignant melanoma (Combination therapy)
  • 06 Jul 2017 Dana-Farber Cancer Institute, in collaboration with Neon Therapeutics and Oncovir, plans a phase I trial for Chronic lymphocytic leukaemia (First-line therapy) in USA (NCT03219450)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top